PODD - Insulet targets 16%-20% U.S. Omnipod growth for 2025 with expanded type 2 diabetes market reach February, 20 2025 11:37 PM Insulet Corporation 2025-02-20 23:37:39 ET More on Insulet Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript Insulet Non-GAAP EPS of $1.15 beats by $0.13, revenue of $597.5M beats by $15.48M v Seeking Alpha’s Quant Rating on Insulet Historical earnings data for Insulet For further details see: Insulet targets 16%-20% U.S. Omnipod growth for 2025 with expanded type 2 diabetes market reach